Zobrazeno 1 - 10
of 23
pro vyhledávání: '"M O, Karlsson"'
Autor:
C H, van der Wouden, A, Cambon-Thomsen, E, Cecchin, K C, Cheung, C L, Dávila-Fajardo, V H, Deneer, V, Dolžan, M, Ingelman-Sundberg, S, Jönsson, M O, Karlsson, M, Kriek, C, Mitropoulou, G P, Patrinos, M, Pirmohamed, M, Samwald, E, Schaeffeler, M, Schwab, D, Steinberger, J, Stingl, G, Sunder-Plassmann, G, Toffoli, R M, Turner, M H, van Rhenen, J J, Swen, H-J, Guchelaar
Publikováno v:
Clinical pharmacology and therapeutics. 102(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d241d37e894b9fbdcfbcdd8d798e5aa4
https://pubmed.ncbi.nlm.nih.gov/28027596
https://pubmed.ncbi.nlm.nih.gov/28027596
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
As biomarkers are lacking, multi‐item questionnaire‐based tools like the Positive and Negative Syndrome Scale (PANSS) are used to quantify disease severity in schizophrenia. Analyzing composite PANSS scores as continuous data discards information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3870645d823cd5f5056f47c81aabcf81
https://pubmed.ncbi.nlm.nih.gov/28571119
https://pubmed.ncbi.nlm.nih.gov/28571119
Publikováno v:
British Journal of Clinical Pharmacology. 43:373-381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a8ee9651ba8c5e739e3938f1e74b6e7
https://doi.org/10.1111/j.1365-2125.1997.00571.x
https://doi.org/10.1111/j.1365-2125.1997.00571.x
Autor:
F Mentré, M O Karlsson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Pfizer scientists present the population PK guidance that they recently developed and implemented.1 We welcome the initiative which serves multiple purposes: (i) provide Pfizer with feedback whether their practices are in line with the scientific com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a98601065cc14e5b65070a58254de13
https://pubmed.ncbi.nlm.nih.gov/23836284
https://pubmed.ncbi.nlm.nih.gov/23836284
Publikováno v:
European journal of clinical investigation. 33(6)
The small intestine is receiving increased attention for its importance in drug metabolism. However, knowledge of the intervariability and regulation of the enzymes involved, cytochrome p450 and P-Glycoproteins (CYP and Pgp), is poor when compared wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0e45392a2a4b00e8a4381f0c5a4aff7f
https://pubmed.ncbi.nlm.nih.gov/12795646
https://pubmed.ncbi.nlm.nih.gov/12795646
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 299(3)
CHS 828 is a novel drug belonging to the cyanoguanidines. It has shown promising anticancer activity in many preclinical systems and is currently in early clinical trials. Our aim in this study was to assess the growth inhibitory effect of CHS 828 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53b79c516645cf708a5f2420d9d0d8ba
https://pubmed.ncbi.nlm.nih.gov/11714905
https://pubmed.ncbi.nlm.nih.gov/11714905
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 28(3)
The objectives of this study were to assess the difference between actual and nominal significance levels, as judged by the likelihood ratio test, for hypothesis tests regarding covariate effects using NONMEM, and to study what factors influence thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ce30da041d5bc03edef1c76b32693576
https://pubmed.ncbi.nlm.nih.gov/12518711
https://pubmed.ncbi.nlm.nih.gov/12518711
Publikováno v:
British journal of clinical pharmacology. 51(1)
The purpose of this study was to characterize the relationship between the degree of anticoagulation, assessed by APTT, and the plasma concentration of inogatran in healthy subjects and in patients with coronary artery disease.Data from five phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::698d3a48aeae197cff4833c9bb141e9a
https://pubmed.ncbi.nlm.nih.gov/11167667
https://pubmed.ncbi.nlm.nih.gov/11167667
Publikováno v:
British journal of clinical pharmacology. 51(1)
To assess the pharmacodynamics of moxonidine in patients with functional NYHA Class II-III congestive heart failure (CHF).A parallel population pharmacokinetic/pharmacodynamic (PK/PD) analysis was performed to assess the effect of moxonidine (0.1, 0.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8baf8852cba8888e195cee5669964739
https://pubmed.ncbi.nlm.nih.gov/11167663
https://pubmed.ncbi.nlm.nih.gov/11167663
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 294(3)
The aim of this study was to elucidate time dependence in the development of rebound effect and to quantify the cardiovascular effects of chronic l-propranolol infusions in spontaneously hypertensive rats. Heart rate and systolic and diastolic blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::352cf218748079ab30fea33b43c49835
https://pubmed.ncbi.nlm.nih.gov/10945878
https://pubmed.ncbi.nlm.nih.gov/10945878